Top Markets
Coin of the day
Theseus Pharmaceuticals, Inc. Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc.

THRX
Classement en actions #19949
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on... Theseus Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and bringing to market targeted treatments for cancer patients. Their leading investigational compound, THE-630, is a pan-KIT inhibitor undergoing Phase I clinical trials for treating gastrointestinal stromal tumors. The company is also advancing a fourth-generation EGFR inhibitor specifically designed to combat the C797S EGFR mutation, which confers resistance to initial or later-line osimertinib therapy in individuals with non-small cell lung cancer. All their research and development efforts aim to overcome drug resistance mutations within key driver oncogenes, which are mutated genes that promote cancer. Founded in 2017, the company operates out of Cambridge, Massachusetts.
Prix de l'action
$4.06
Dernière synchronisation: 2024-02-23
Capitalisation boursière
$145.61M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Theseus Pharmaceuticals, Inc. (THRX)

Catégorie

Ratio P/B pour Theseus Pharmaceuticals, Inc. (THRX)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Theseus Pharmaceuticals, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Theseus Pharmaceuticals, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH